Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionDual CCR2/CCR5 chemokine antagonist
Molecular Target CC chemokine receptor 2 (CCR2) (CD192) ; CC chemokine receptor 5 (CCR5) (CD195)
Mechanism of ActionCC chemokine receptor 2 (CCR2) antagonist; CC chemokine receptor 5 (CCR5) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetic nephropathy
Indication DetailsTreat diabetic kidney disease
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today